Does EssilorLuxottica Société anonyme's (EPA:EL) Past Performance Indicate A Stronger Future?

Investors with a long-term horizong may find it valuable to assess EssilorLuxottica Société anonyme's (ENXTPA:EL) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. Below is my commentary, albiet very simple and high-level, on how EssilorLuxottica Société anonyme is currently performing.

Check out our latest analysis for EssilorLuxottica Société anonyme

Advertisement

Did EL beat its long-term earnings growth trend and its industry?

EL's trailing twelve-month earnings (from 30 June 2019) of €1.2b has increased by 4.3% compared to the previous year.

However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 8.9%, indicating the rate at which EL is growing has slowed down. To understand what's happening, let's examine what's going on with margins and if the whole industry is facing the same headwind.

ENXTPA:EL Income Statement, September 9th 2019
ENXTPA:EL Income Statement, September 9th 2019

In terms of returns from investment, EssilorLuxottica Société anonyme has fallen short of achieving a 20% return on equity (ROE), recording 4.0% instead. Furthermore, its return on assets (ROA) of 2.7% is below the FR Luxury industry of 6.5%, indicating EssilorLuxottica Société anonyme's are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for EssilorLuxottica Société anonyme’s debt level, has declined over the past 3 years from 14% to 4.4%.

What does this mean?

While past data is useful, it doesn’t tell the whole story. Positive growth and profitability are what investors like to see in a company’s track record, but how do we properly assess sustainability? I suggest you continue to research EssilorLuxottica Société anonyme to get a more holistic view of the stock by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for EL’s future growth? Take a look at our free research report of analyst consensus for EL’s outlook.
  2. Financial Health: Are EL’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the trailing twelve months from 30 June 2019. This may not be consistent with full year annual report figures.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About ENXTPA:EL

EssilorLuxottica Société anonyme

Designs, manufactures, and distributes ophthalmic lenses, frames, sunglasses, and instruments and equipment in North America, the Middle East, Africa, Europe, Latin America, and the Asia-Pacific.

Adequate balance sheet average dividend payer.

Advertisement

Weekly Picks

LO
Lou_Basenese
VTIX logo
Lou_Basenese on Virtuix Holdings ·

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’sMost Mispriced AI Story

Fair Value:US$7.551.2% undervalued
3 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75034.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
TR
tripledub
INTU logo
tripledub on Intuit ·

A Wonderful Business at a Not-So-Wonderful Price

Fair Value:US$56053.9% undervalued
50 users have followed this narrative
2 users have commented on this narrative
28 users have liked this narrative
TA
Talos
HYFT logo
Talos on MindWalk Holdings ·

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect

Fair Value:US$8.2782.0% undervalued
17 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
RCKT logo
AnimalDoctorKwon on Rocket Pharmaceuticals ·

The Structural Disconnect Between Market Valuation and Operational Maturity

Fair Value:US$1066.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
AKBA logo
AnimalDoctorKwon on Akebia Therapeutics ·

Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Fair Value:US$77.2998.6% undervalued
6 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
MBIO logo
AnimalDoctorKwon on Mustang Bio ·

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Fair Value:US$1.861.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7444.6% undervalued
67 users have followed this narrative
0 users have commented on this narrative
16 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9638.3% undervalued
61 users have followed this narrative
9 users have commented on this narrative
18 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17057.1% undervalued
51 users have followed this narrative
0 users have commented on this narrative
13 users have liked this narrative